The role of postimplant dosimetry in predicting permanent brachytherapy effectiveness in patients with low and intermediate risk prostate cancer

Brachytherapy is a high-tech and minimally-invasive treatment for prostate cancer ( PCa ). Monitoring the effectiveness of brachytherapy is often made only on the basis of PSA dynamics. At the same time there is a simple and affordable tool of quality control - postimplantation dosimetry (PDA) based on the data of postoperative computed tomography (CT). The aim of our work was to analyze the disease-free survival of patients undergoing brachytherapy, depending on postoperative dosimetric parameters. Materials and Methods. The analysis included 117 patients who meet the following criteria: disease stage T1-T2c, low or intermediate risk of disease (criteria D' Amico), follow-up period of 5 years or more, and performed PDA, which was carried out based on the day 30 CT data. According to the results of PDA patients were divided into 2 groups: group I figure D90 was ≥140 Gray, group II 0, 05). On average, 90% of the prostate volume (D90) received a dose of 167.4 Gy in the first group and 134.4 Gy in the second. 5-year bBRV was significantly higher in the group D90 ≥140 Gy, compared to patients with a dose of